Trial Profile
Phase II Multicentric Study: Efficacy Evaluation of Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy on Disease-free-survival (DFS) in Patients With Resectable Head and Neck Mucosal Melanoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms IMMUQ
- 17 May 2023 Oral lenvatinib has been added as a study drug, maintenance therapy with pembrolizumab will also be studied along with neo-adjuvant therapy.
- 17 May 2023 Planned number of patients changed from 50 to 60.
- 02 Jan 2019 Planned End Date changed from 1 May 2025 to 1 Nov 2026.